Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease Copenhagen, Denmark, 23 September 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces the establishment of its scientific advisory board (SAB) comprising global leaders in carbohydrate chemistry, the regulation […]

Copenhagen and Aarhus, Denmark, 23 June 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces the appointment of Andrew Hotchkiss as Chief Executive Officer (CEO). Andrew brings more than 30 years of global experience in the pharmaceutical and biotechnology industries. He joins […]